Product Description
Ataciguat is a novel anthranilic acid derivative that belongs to a new structural class of sGC activators which are capable of activating the oxidized form of sGC. Ataciguat, a nitric oxide-independent soluble guanylate cyclase activator, is being developed by Sanofi (previously sanofi-aventis), in collaboration with Mayo Clinic and National Center for Advancing Translational Sciences. Ataciguat is in phase II clinical trials for the treatment of aortic valve stenosis (Sourced from: https://drugs.ncats.io/drug/QP166M390Q)
Mechanisms of Action: sGC Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Canada, Czech Republic, Portugal, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Aortic Valve Stenosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07001800 |
KATALYST-AV | P3 |
Recruiting |
Aortic Valve Stenosis |
2028-08-31 |
9% |
2026-04-14 |
Primary Endpoints|Treatments |
2025-522176-86-01 |
ATA-301 | P3 |
Not yet recruiting |
Aortic Valve Stenosis |
2030-09-30 |